SG Americas Securities LLC Sells 20,073 Shares of Repligen Co. (NASDAQ:RGEN)

SG Americas Securities LLC lessened its holdings in Repligen Co. (NASDAQ:RGEN - Free Report) by 74.0% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 7,042 shares of the biotechnology company's stock after selling 20,073 shares during the period. SG Americas Securities LLC's holdings in Repligen were worth $1,266,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Invesco Ltd. increased its stake in Repligen by 3.9% in the first quarter. Invesco Ltd. now owns 1,756,157 shares of the biotechnology company's stock valued at $330,315,000 after acquiring an additional 65,550 shares during the last quarter. State Street Corp grew its stake in shares of Repligen by 0.9% during the second quarter. State Street Corp now owns 1,651,310 shares of the biotechnology company's stock valued at $233,594,000 after buying an additional 14,647 shares during the last quarter. Artisan Partners Limited Partnership lifted its stake in shares of Repligen by 11.3% in the 3rd quarter. Artisan Partners Limited Partnership now owns 1,556,873 shares of the biotechnology company's stock valued at $247,558,000 after acquiring an additional 157,807 shares during the last quarter. Brown Capital Management LLC lifted its stake in shares of Repligen by 0.3% in the 2nd quarter. Brown Capital Management LLC now owns 1,445,213 shares of the biotechnology company's stock valued at $204,440,000 after acquiring an additional 4,845 shares during the last quarter. Finally, Wellington Management Group LLP lifted its stake in shares of Repligen by 2.1% in the 3rd quarter. Wellington Management Group LLP now owns 1,396,610 shares of the biotechnology company's stock valued at $222,075,000 after acquiring an additional 29,215 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company's stock.

Insider Activity at Repligen

In related news, COO James Bylund sold 4,373 shares of the business's stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $198.08, for a total transaction of $866,203.84. Following the completion of the transaction, the chief operating officer now directly owns 14,135 shares in the company, valued at $2,799,860.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, VP Ralf Kuriyel sold 3,517 shares of the business's stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $193.73, for a total transaction of $681,348.41. Following the completion of the sale, the vice president now owns 24,260 shares of the company's stock, valued at $4,699,889.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO James Bylund sold 4,373 shares of the company's stock in a transaction dated Friday, February 23rd. The shares were sold at an average price of $198.08, for a total transaction of $866,203.84. Following the sale, the chief operating officer now directly owns 14,135 shares of the company's stock, valued at approximately $2,799,860.80. The disclosure for this sale can be found here. Insiders sold 25,597 shares of company stock worth $5,039,532 over the last three months. Company insiders own 1.10% of the company's stock.

Wall Street Analysts Forecast Growth

RGEN has been the subject of a number of recent research reports. Benchmark lowered Repligen from a "buy" rating to a "hold" rating in a research note on Monday, December 4th. Stifel Nicolaus upped their target price on Repligen from $165.00 to $207.00 and gave the stock a "buy" rating in a report on Thursday, February 22nd. JPMorgan Chase & Co. upped their target price on Repligen from $170.00 to $210.00 and gave the stock an "overweight" rating in a report on Wednesday, December 20th. Finally, KeyCorp upped their target price on Repligen from $210.00 to $220.00 and gave the stock an "overweight" rating in a report on Thursday, February 15th. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $196.70.

Repligen Stock Down 0.4 %

NASDAQ RGEN traded down $0.83 on Friday, hitting $183.92. The stock had a trading volume of 337,956 shares, compared to its average volume of 371,972. The business's fifty day moving average price is $194.79 and its 200 day moving average price is $172.16. The company has a debt-to-equity ratio of 0.26, a current ratio of 7.02 and a quick ratio of 5.75. Repligen Co. has a 52-week low of $110.45 and a 52-week high of $211.13. The stock has a market cap of $10.26 billion, a price-to-earnings ratio of 255.45, a price-to-earnings-growth ratio of 6.02 and a beta of 1.03.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported $0.33 EPS for the quarter, hitting the consensus estimate of $0.33. Repligen had a net margin of 6.51% and a return on equity of 5.00%. The business had revenue of $155.74 million during the quarter, compared to the consensus estimate of $155.38 million. During the same period in the previous year, the firm posted $0.68 earnings per share. The business's revenue for the quarter was down 16.6% compared to the same quarter last year. Equities research analysts anticipate that Repligen Co. will post 1.46 earnings per share for the current year.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.